{
    "clinical_study": {
        "@rank": "97442", 
        "arm_group": [
            {
                "arm_group_label": "Young adults", 
                "arm_group_type": "Experimental", 
                "description": "To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method"
            }, 
            {
                "arm_group_label": "Elderly adults", 
                "arm_group_type": "Experimental", 
                "description": "To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method"
            }
        ], 
        "brief_summary": {
            "textblock": "To find out the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes\n      from profound rocuronium-induced neuromuscular block in young and elderly adult patients."
        }, 
        "brief_title": "The Dose of Sugammadex for Rapid Reversal of Profound Neuromuscular Block in Young and Elderly Patients", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Anesthesia Recovery Period, Neuromuscular Blockade", 
        "detailed_description": {
            "textblock": "A previous study reported that elderly patients required a longer time to recover from\n      rocuronium induced neuromuscular block compared to younger patients. Therefore, the aim of\n      this study is to find out the dose of sugammadex for rapid recovery from profound\n      neuromuscular block in young and elderly adult patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  20-40 years or \u226570 years ASA class I-II patients who received surgery less than 2\n             hours.\n\n        Exclusion Criteria:\n\n          -  anticipated difficult intubation\n\n          -  neuromuscular, hepatic or renal disorders\n\n          -  drug allergy\n\n          -  body mass index >30 kg/m2 or body mass index <18 kg/m2\n\n          -  emergency surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01890057", 
            "org_study_id": "4-2013-0280"
        }, 
        "intervention": {
            "arm_group_label": [
                "Young adults", 
                "Elderly adults"
            ], 
            "description": "The dose of sugammadex", 
            "intervention_name": "Sugammadex", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block", 
            "safety_issue": "Yes", 
            "time_frame": "2 hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01890057"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Severance Hospital", 
            "investigator_full_name": "So Yeon Kim", 
            "investigator_title": "Assistant professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Severance Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Severance Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}